DK1853305T3 - Survivin-peptidvaccine - Google Patents

Survivin-peptidvaccine Download PDF

Info

Publication number
DK1853305T3
DK1853305T3 DK06704603.7T DK06704603T DK1853305T3 DK 1853305 T3 DK1853305 T3 DK 1853305T3 DK 06704603 T DK06704603 T DK 06704603T DK 1853305 T3 DK1853305 T3 DK 1853305T3
Authority
DK
Denmark
Prior art keywords
hla
peptide
survivin
seq
vaccine composition
Prior art date
Application number
DK06704603.7T
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Application granted granted Critical
Publication of DK1853305T3 publication Critical patent/DK1853305T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (11)

1. Vaccinepræparat omfattende i. ét eller flere HLA-A2-restrictede survivinpeptider, som er valgt fra gruppen bestående af LLLGEFLKL (SEQ ID NO. 4) og LMLGEFLKL (SEQ ID NO. 5), og ii. en adjuvans, som er formuleret til en vand-i-olie-emulsion, der omfatter en mineralolie og et overfladeaktivt middel, hvor adjuvansen omfatter op til 14,5 volumenprocent af det overfladeaktive middel, til anvendelse som lægemiddel.
2. Vaccinepræparat ifølge krav 1, hvor det overfladeaktive middel er mannidoleat.
3. Vaccinepræparat ifølge krav 1-2, hvor én survivinpeptidvariant består af: LMLGEFLKL (SEQ ID NO. 5).
4. Vaccinepræparat ifølge et hvilket som helst af kravene 1-3, som desuden omfatter ét eller flere peptider eller peptidvarianter, som er valgt fra grupperne ML-IAP-, BCL-2-, BCL-X-, MCL-1- eller TRAG-3-peptider eller peptidvarianter deraf, som er i stand til at binde til et HLA klasse 1-molekyle.
5. Vaccinepræparat ifølge et hvilket som helst af kravene 1-4, som desuden omfatter ét eller flere peptider eller peptidvarianter, som er valgt fra grupperne ML-IAP-, BCL-X-, MCL-1- eller TRAG-3-peptider eller peptidvarianter deraf, som er i stand til at binde til et HLA klasse 1-molekyle.
6. Vaccinepræparat ifølge et hvilket som helst af kravene 1-5, som omfatter en sekundær aktiv bestanddel, der er valgt fra gruppen bestående af: i. et anticancerlægemiddel ii. et kemoterapeutisk middel og iii. en angiogeneseinhibitor.
7. Anvendelse af et vaccinepræparat ifølge et hvilket som helst af kravene 1-6 til fremstilling af et lægemiddel til behandling af cancer.
8. Vaccinepræparat ifølge et hvilket som helst af kravene 1-6 til anvendelse i en fremgangsmåde til behandling af cancer.
9. Anvendelse af et vaccinepræparat ifølge et hvilket som helst af kravene 1-6 til fremstilling af et lægemiddel til inhibering af angiogenese.
10. Vaccinepræparat ifølge et hvilket som helst af kravene 1-6 til anvendelse i en fremgangsmåde til inhibering af angiogenese.
11. Kit-in-parts omfattende: iv. et vaccinepræparat ifølge et hvilket som helst af kravene 1-6 og v. et sekundært lægemiddel, hvor det sekundære lægemiddel er et kemoterapeutisk middel eller en angiogeneseinhibitor.
DK06704603.7T 2005-02-04 2006-02-03 Survivin-peptidvaccine DK1853305T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04
US65075105P 2005-02-07 2005-02-07
PCT/DK2006/000061 WO2006081826A2 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Publications (1)

Publication Number Publication Date
DK1853305T3 true DK1853305T3 (da) 2014-12-01

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06704603.7T DK1853305T3 (da) 2005-02-04 2006-02-03 Survivin-peptidvaccine

Country Status (16)

Country Link
US (1) US20110091489A1 (da)
EP (3) EP1853305B1 (da)
JP (2) JP2008528643A (da)
KR (1) KR20070108536A (da)
CN (3) CN101111260B (da)
AU (1) AU2006209951B2 (da)
BR (1) BRPI0607326B8 (da)
CA (1) CA2593714C (da)
DK (1) DK1853305T3 (da)
ES (1) ES2523172T3 (da)
HK (1) HK1112367A1 (da)
MX (1) MX2007009219A (da)
PL (1) PL1853305T3 (da)
RU (1) RU2396088C2 (da)
WO (1) WO2006081826A2 (da)
ZA (1) ZA200705943B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465A1 (en) 2007-07-03 2020-03-11 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) * 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
WO2009106073A2 (en) * 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
FR2955775B1 (fr) * 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
EP3536334B1 (en) 2012-05-16 2021-06-23 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
EP2978450B1 (en) * 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
AU2014365888B2 (en) * 2013-12-16 2018-12-06 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
AU2016355926A1 (en) 2015-11-18 2018-05-31 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:C polynucleotide adjuvant and a lipid-based adjuvant
TWI628189B (zh) * 2016-02-23 2018-07-01 財團法人國家衛生研究院 脂質化存活素（ｓｕｒｖｉｖｉｎ）及其用以預防及治療癌症之用途
KR20230131498A (ko) 2016-09-21 2023-09-13 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
JP7437939B2 (ja) 2017-03-03 2024-02-26 トレオス バイオ リミテッド 集団に基づいた免疫原性ペプチドの同定のプラットフォーム
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS DIRECTED AGAINST COMMON ANTIGENS
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ATE373486T1 (de) * 1992-09-30 2007-10-15 Univ Ohio State Res Found Impfstoffe zur behandlung von kolonkrebs
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
ATE414149T1 (de) 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
AU2001272491A1 (en) * 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
ES2311558T3 (es) * 2000-10-20 2009-02-16 Genetics Institute, Inc. Uso de inhibidores de la il-13 para el tratamiento de tumores.
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
WO2004050111A2 (en) * 2002-12-02 2004-06-17 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment
CN101851275A (zh) * 2003-01-15 2010-10-06 株式会社国际癌症免疫研究所 二聚体化肽
EP2338509B1 (en) * 2003-06-27 2014-06-18 International Institute of Cancer Immunology, Inc. Method of selecting patients suitable for WT1 vaccine
JP4926714B2 (ja) * 2003-11-19 2012-05-09 サーバック エーピーエス Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用

Also Published As

Publication number Publication date
BRPI0607326B1 (pt) 2021-01-19
EP2329841A1 (en) 2011-06-08
ES2523172T3 (es) 2014-11-21
BRPI0607326B8 (pt) 2021-05-25
CN103169958A (zh) 2013-06-26
EP1853305A2 (en) 2007-11-14
JP2008528643A (ja) 2008-07-31
CN101111260A (zh) 2008-01-23
AU2006209951A1 (en) 2006-08-10
CN101111260B (zh) 2013-03-20
ZA200705943B (en) 2008-12-31
RU2007133103A (ru) 2009-03-10
CN103143004A (zh) 2013-06-12
EP1853305B1 (en) 2014-08-20
CA2593714A1 (en) 2006-08-10
RU2396088C2 (ru) 2010-08-10
JP2012149101A (ja) 2012-08-09
US20110091489A1 (en) 2011-04-21
AU2006209951B2 (en) 2011-04-14
EP2329840A1 (en) 2011-06-08
KR20070108536A (ko) 2007-11-12
CA2593714C (en) 2013-09-10
WO2006081826A3 (en) 2007-02-15
JP5631357B2 (ja) 2014-11-26
WO2006081826A2 (en) 2006-08-10
BRPI0607326A2 (pt) 2009-09-01
MX2007009219A (es) 2008-01-16
PL1853305T3 (pl) 2015-02-27
HK1112367A1 (en) 2008-08-29

Similar Documents

Publication Publication Date Title
DK1853305T3 (da) Survivin-peptidvaccine
RU2367468C2 (ru) БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
EP1242049A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
US8043623B2 (en) Immunogenic peptides for the treatment of prostate and breast cancer
US20030224036A1 (en) Hla class I a2 tumor associated antigen peptides and vaccine compositions
AU2011203536B2 (en) Survivin peptide vaccine
AU2011203535B2 (en) Survivin peptide vaccine
US7687465B2 (en) Therapeutic cancer vaccine
EP1618130B1 (en) Therapeutic cancer vaccine
WO2005049072A2 (en) Therapeutic cancer vaccine with fragments of trag-3
JP2022116237A (ja) ネオ抗原およびその使用方法